KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Free Cash Flow (2016 - 2025)

Neogenomics' Free Cash Flow history spans 16 years, with the latest figure at -$6.5 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 117.07% year-over-year to -$6.5 million; the TTM value through Dec 2025 reached -$21.8 million, down 462.3%, while the annual FY2025 figure was -$21.8 million, 462.3% down from the prior year.
  • Free Cash Flow reached -$6.5 million in Q4 2025 per NEO's latest filing, down from $570000.0 in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $38.2 million in Q4 2024 to a low of -$56.1 million in Q3 2021.
  • Average Free Cash Flow over 5 years is -$8.6 million, with a median of -$9.3 million recorded in 2022.
  • Peak YoY movement for Free Cash Flow: crashed 665.24% in 2021, then surged 1538.53% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at $31.1 million in 2021, then crashed by 126.46% to -$8.2 million in 2022, then skyrocketed by 230.51% to $10.7 million in 2023, then skyrocketed by 256.58% to $38.2 million in 2024, then tumbled by 117.07% to -$6.5 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Free Cash Flow are -$6.5 million (Q4 2025), $570000.0 (Q3 2025), and $14.0 million (Q2 2025).